Abbott Laboratories has agreed to a US$385 million settlement tied to its 2022 infant formula recall and the shutdown of its Sturgis plant. The agreement resolves civil claims from families, states, and other plaintiffs who alleged product safety failures and gaps in compliance with federal standards, and it follows investigations by the U.S. Department of Justice and multiple states into Abbott's infant formula operations. The settlement, which covers only the civil claims and includes no admission of liability, gives Abbott clearer visibility on its infant nutrition liabilities and removes a high-profile government probe that had been flagged as an ongoing litigation risk. Abbott Laboratories is a large global healthcare manufacturer with a US$178.4b market cap, so issues in its infant formula segment sit alongside a broad mix of medical equipment and other health products. Investors will be watching for concrete follow-through on manufacturing and quality control, especially at Sturgis and Casa Grande, with key signposts in future FDA or USDA plant inspection findings and any new disclosures on remediation spending or compliance milestones in upcoming quarterly filings and earnings calls.
Abbott LaboratoriesAbbott's $385M settlement resolves civil claims and removes a high-profile DOJ/state probe into its 2022 infant formula recall, clearing a flagged litigation risk.
